{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:05:51Z","timestamp":1788973551666,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,12,23]],"date-time":"2011-12-23T00:00:00Z","timestamp":1324598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Neurol Neurosci Rep"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s11910-011-0245-4","type":"journal-article","created":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T06:59:02Z","timestamp":1324537142000},"page":"132-137","source":"Crossref","is-referenced-by-count":50,"title":["Nocebo in Headaches: Implications for Clinical Practice and Trial Design"],"prefix":"10.1007","volume":"12","author":[{"given":"Dimos D.","family":"Mitsikostas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,23]]},"reference":[{"key":"245_CR1","first-page":"203","volume":"95","author":"WP Kennedy","year":"1961","unstructured":"Kennedy WP. The nocebo reaction. Med World. 1961;95:203\u20135.","journal-title":"Med World"},{"key":"245_CR2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jama.287.5.622","volume":"287","author":"AJ Barsky","year":"2002","unstructured":"Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287:622\u20137.","journal-title":"JAMA"},{"key":"245_CR3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuron.2008.06.030","volume":"59","author":"P Enck","year":"2008","unstructured":"Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. Neuron. 2008;59:195\u2013206.","journal-title":"Neuron"},{"key":"245_CR4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/1352458510370793","volume":"16","author":"D Papadopoulos","year":"2010","unstructured":"Papadopoulos D, Mitsikostas DD. Nocebo effects in multiple sclerosis trials: a meta-analysis. Mult Scler. 2010;16:816\u201328.","journal-title":"Mult Scler"},{"key":"245_CR5","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.pain.2011.01.043","volume":"152","author":"AI Laarhoven van","year":"2011","unstructured":"van Laarhoven AI, Vogelaar ML, Wilder-Smith OH, et al. Induction of nocebo and placebo effects on itch and pain by verbal suggestions. Pain. 2011;152:1486\u201394. Epub 2011 Feb 24.","journal-title":"Pain"},{"key":"245_CR6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1213\/ANE.0b013e3181cc5727","volume":"110","author":"D Varelmann","year":"2010","unstructured":"Varelmann D, Pancaro C, Cappiello EC, Camann WR. Nocebo-induced hyperalgesia during local anesthetic injection. Anesth Analg. 2010;110:868\u201370.","journal-title":"Anesth Analg"},{"key":"245_CR7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.pain.2008.02.006","volume":"136","author":"L Colloca","year":"2008","unstructured":"Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain. 2008;136:211\u20138.","journal-title":"Pain"},{"key":"245_CR8","doi-asserted-by":"crossref","unstructured":"Benedetti F, Lanotte M, Lopiano L, Colloca L. When words are painful: unraveling the mechanisms of the nocebo effect. Neuroscience. 2007 29;147:260\u201371.","DOI":"10.1016\/j.neuroscience.2007.02.020"},{"key":"245_CR9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3959(03)00073-3","volume":"105","author":"L Vase","year":"2003","unstructured":"Vase L, Robinson ME, Verne GN, Price DD. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain. 2003;105:17\u201325.","journal-title":"Pain"},{"key":"245_CR10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.pec.2011.04.034","volume":"84","author":"F Benedetti","year":"2011","unstructured":"Benedetti F, Amanzio M. The placebo response: How words and rituals change the patient's brain. Patient Educ Couns. 2011;84:413\u20139.","journal-title":"Patient Educ Couns"},{"key":"245_CR11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0301-0082(97)00006-3","volume":"52","author":"F Benedetti","year":"1997","unstructured":"Benedetti F, Amanzio M. The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Prog Neurobiol. 1997;52:109\u201325.","journal-title":"Prog Neurobiol"},{"key":"245_CR12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3959(97)03346-0","volume":"71","author":"F Benedetti","year":"1997","unstructured":"Benedetti F, Amanzio M, Casadio C, et al. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide. Pain. 1997;71:135\u201340.","journal-title":"Pain"},{"key":"245_CR13","doi-asserted-by":"crossref","first-page":"12014","DOI":"10.1523\/JNEUROSCI.2947-06.2006","volume":"26","author":"F Benedetti","year":"2006","unstructured":"Benedetti F, Amanzio M, Vighetti S, Asteggiano G. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci. 2006;26:12014\u201322.","journal-title":"J Neurosci"},{"key":"245_CR14","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1523\/JNEUROSCI.2944-08.2008","volume":"28","author":"J Kong","year":"2008","unstructured":"Kong J, Gollub RL, Polich G, et al. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. J Neurosci. 2008;28:13354\u201362.","journal-title":"J Neurosci"},{"key":"245_CR15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2007.34","volume":"65","author":"DJ Scott","year":"2008","unstructured":"Scott DJ, Stohler CS, Egnatuk CM, et al. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry. 2008;65:220\u201331.","journal-title":"Arch Gen Psychiatry"},{"key":"245_CR16","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/nm.2229","volume":"16","author":"I Tracey","year":"2010","unstructured":"\u2022 Tracey I. Getting the pain you expect: mechanisms of placebo, nocebo and reappraisal effects in humans. Nat Med. 2010;16:1277-83. This is an extensive review of all biochemical and molecular mechanisms underlying nocebo and placebo.","journal-title":"Nat Med"},{"key":"245_CR17","first-page":"1111","volume":"43","author":"WR Evans","year":"2003","unstructured":"Evans WR. Headaches and the nocebo effect. Headache. 2003;43:1111\u20135.","journal-title":"Headache"},{"key":"245_CR18","doi-asserted-by":"crossref","unstructured":"Colloca L, Miller FG. The nocebo effect and its relevance for clinical practice. Psychosom Med. 2011 Aug 23. [Epub ahead of print]","DOI":"10.1097\/PSY.0b013e3182294a50"},{"key":"245_CR19","doi-asserted-by":"crossref","first-page":"d5076","DOI":"10.1136\/bmj.d5076","volume":"343","author":"KR Merikangas","year":"2011","unstructured":"Merikangas KR, Cui L, Richardson AK, et al. Magnitude, impact, and stability of primary headache subtypes: 30\u00a0year prospective Swiss cohort study. BMJ. 2011;343:d5076.","journal-title":"BMJ"},{"issue":"Suppl 2","key":"245_CR20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1526-4610.2011.01954.x","volume":"51","author":"RB Lipton","year":"2011","unstructured":"Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache. 2011;51 Suppl 2:77\u201383.","journal-title":"Headache"},{"key":"245_CR21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1468-2982.2003.00530.x","volume":"23","author":"U Reuter","year":"2003","unstructured":"Reuter U, Sanchez del Rio M, Carpay JA, et al. GSK headache masters program: placebo adverse events in headache trials: headache as an adverse event of placebo. Cephalalgia. 2003;23:496\u2013503.","journal-title":"Cephalalgia"},{"key":"245_CR22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1468-2982.2004.00817.x","volume":"25","author":"E Loder","year":"2004","unstructured":"Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia. 2004;25:124\u201331.","journal-title":"Cephalalgia"},{"key":"245_CR23","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.pain.2009.07.010","volume":"146","author":"M Amanzion","year":"2009","unstructured":"\u2022\u2022 Amanzion M, Corazzini LL, Vase L, Benedetti F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 2009; 146: 261\u2013269. This is a systematic review of placebo-controlled trials for migraine treatment (either symptomatic or preventive). The authors aimed to evaluate the AEs recorded by patients treated with specific class antimigraine agents in relation to the AEs recorded by the patients treated with placebo. They found that the AEs in both groups were closely similar, indicating that nocebo adverse events are not un-specific symptoms. In the contrary, nocebo consists of drug-related AEs that the patients have been told by the investigators that they may experience. This finding is in line with the expectation theory of placebo and nocebo.","journal-title":"Pain"},{"key":"245_CR24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/0333102410391485","volume":"31","author":"DD Mitsikostas","year":"2011","unstructured":"\u2022\u2022 Mitsikostas DD, Mantonakis LI, Chalarakis NG. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 2011;31:550-61. In this systematic review, all placebo-controlled randomized trials for the treatment of any primary headache, published in the last decade, were analyzed to estimate the pooled average of placebo-treated patients who experienced any AE, or discontinued treatment due to AE. One out 20 patients treated for prophylaxis of migraine was discontinued due to AEs, although treated with placebo. Nocebo dropout was equal in trials for TTH. This finding has essential significance for both clinical practice and trial designing.","journal-title":"Cephalalgia"},{"key":"245_CR25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/157488911794079109","volume":"6","author":"M Amanzio","year":"2011","unstructured":"Amanzio M. Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials? Recent Pat CNS Drug Discov. 2011;6:41\u20137.","journal-title":"Recent Pat CNS Drug Discov"},{"key":"245_CR26","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","volume":"50","author":"DW Dodick","year":"2010","unstructured":"Dodick DW, Turkel CC, DeGryse RE, et al. PREEMPT Chronic Migraine Study Group: OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921\u201336.","journal-title":"Headache"},{"issue":"Suppl 1","key":"245_CR27","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1007\/s11739-010-0444-z","volume":"5","author":"GC Manzoni","year":"2010","unstructured":"Manzoni GC, Torelli P. Epidemiological classification and social impact of chronic headache. Intern Emerg Med. 2010;5 Suppl 1:S1\u20135.","journal-title":"Intern Emerg Med"},{"key":"245_CR28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10194-010-0217-0","volume":"11","author":"LJ Stovner","year":"2010","unstructured":"Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11:289\u201399.","journal-title":"J Headache Pain"},{"key":"245_CR29","doi-asserted-by":"crossref","unstructured":"Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol. 2011 Aug 3. [Epub ahead of print].","DOI":"10.1007\/s00415-011-6197-4"},{"key":"245_CR30","doi-asserted-by":"crossref","unstructured":"Mitsikostas DD, Chalarakis NG, Mantonakis LI, et al. Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol 2011 Oct 4. doi: 10.1111\/j.1468-1331.2011.03528.x .","DOI":"10.1111\/j.1468-1331.2011.03528.x"},{"key":"245_CR31","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/cncr.24751","volume":"116","author":"M Cruz de la","year":"2010","unstructured":"de la Cruz M, Hui D, Parsons HA, Bruera E. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer. 2010;116:766\u201374.","journal-title":"Cancer"},{"key":"245_CR32","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.neuroimage.2009.04.028","volume":"47","author":"DD Price","year":"2009","unstructured":"Price DD, Craggs JG, Zhou Q, et al. Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo\/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging. NeuroImage. 2009;47:995\u20131001.","journal-title":"NeuroImage"},{"key":"245_CR33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.contraception.2010.06.010","volume":"83","author":"DA Grimes","year":"2011","unstructured":"Grimes DA, Schulz KF. Nonspecific side effects of oral contraceptives: nocebo or noise? Contraception. 2011;83:5\u20139.","journal-title":"Contraception"},{"key":"245_CR34","first-page":"451","volume":"65","author":"J Weissenfeld","year":"2010","unstructured":"Weissenfeld J, Stock S, L\u00fcngen M, Gerber A. The nocebo effect: a reason for patients' non-adherence to generic substitution? Pharmazie. 2010;65:451\u20136.","journal-title":"Pharmazie"},{"key":"245_CR35","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.dld.2010.02.005","volume":"42","author":"P Vernia","year":"2010","unstructured":"Vernia P, Di Camillo M, Foglietta T, et al. Diagnosis of lactose intolerance and the \"nocebo\" effect: the role of negative expectations. Dig Liver Dis. 2010;42:616\u20139.","journal-title":"Dig Liver Dis"},{"key":"245_CR36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000189628","volume":"12","author":"SB Haga","year":"2009","unstructured":"Haga SB, Warner LR, O'Daniel J. The potential of a placebo\/nocebo effect in pharmacogenetics. Public Health Genomics. 2009;12:158\u201362.","journal-title":"Public Health Genomics"}],"container-title":["Current Neurology and Neuroscience Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-011-0245-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11910-011-0245-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11910-011-0245-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T06:13:23Z","timestamp":1561097603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11910-011-0245-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,23]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["245"],"URL":"https:\/\/doi.org\/10.1007\/s11910-011-0245-4","relation":{},"ISSN":["1528-4042","1534-6293"],"issn-type":[{"value":"1528-4042","type":"print"},{"value":"1534-6293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,23]]}}}